2024
HLA DQA1*05 and risk of anti-TNF treatment failure and anti-drug antibody development in children with Crohn's Disease: HLA DQA1*05 and Pediatric Crohn's Disease.
Adler J, Galanko J, Ammoury R, Benkov K, Bousvaros A, Boyle B, Cabrera J, Chun K, Dorsey J, Ebach D, Firestine A, Gulati A, Herfarth H, Jester T, Kaplan J, Leibowitz I, Linville T, Margolis P, Minar P, Molle-Rios Z, Moses J, Olano K, Pashankar D, Pitch L, Saeed S, Samson C, Sandberg K, Steiner S, Strople J, Sullivan J, Wali P, Kappelman M. HLA DQA1*05 and risk of anti-TNF treatment failure and anti-drug antibody development in children with Crohn's Disease: HLA DQA1*05 and Pediatric Crohn's Disease. The American Journal Of Gastroenterology 2024 PMID: 39423015, DOI: 10.14309/ajg.0000000000003135.Peer-Reviewed Original ResearchHLA-DQA1*05Anti-drug antibodiesDQA1*05Anti-drug antibody developmentTreatment failureCrohn's diseaseAnti-TNFPositive patientsDevelopment of anti-drug antibodiesAnti-TNF treatment failureTumor necrosis factor antagonistsIndicator of treatment failureAnti-TNF monotherapyPediatric Crohn's diseaseIncreased treatment failureTrial of childrenYears of ageRandomized trial of childrenOral methotrexatePositive participantsRisk stratificationPediatric dataRandomized trialsIncreased riskPrimary outcome
2005
224 Increased Prevalence of Obesity in Children with Functional Constipation with and Without Fecal Incontinence
Loening-Baucke V, Pashankar D. 224 Increased Prevalence of Obesity in Children with Functional Constipation with and Without Fecal Incontinence. Pediatric Research 2005, 58: 392-392. DOI: 10.1203/00006450-200508000-00253.Peer-Reviewed Original ResearchFecal incontinencePrevalence of obesityYears of ageMorbid obesityFunctional constipationMorbid obeseWell-child visitsRates of obesityObesity clinicConstipated childrenChildren's HospitalMean agePediatric clinicChild visitsHigh prevalenceConstipationIncontinenceHormonal influencesObesityControl groupPrevalenceActivity levelsGender ratioControl boysObese